Document Detail


Role of tenecteplase in pulmonary embolism.
MedLine Citation:
PMID:  20635764     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Patients presenting with pulmonary embolism (PE) have a wide spectrum of clinical severity. Although, some patients may present with frank hemodynamic collapse and cardiac arrest, others may present with asymptomatic PE that is discovered incidentally during work up of another condition. Fibrinolytic therapy is an option in the treatment of patients with PE. A rational approach to decide whether to indicate fibrinolytic therapy is based on assessment of benefits that each patient will derive from fibrinolytic therapy weighed against risk of major bleeding and intracranial hemmorage. There is a clear benefit/risk ratio for fibrinolytic therapy in patients with PE who present with cardiac arrest and in those who are hemodynamically unstable from a massive pulmonary embolism. With proper risk assessment selected patients with stable hemodynamics and right ventricular dysfunction may also benefit from fibrinolytic therapy. This article sets out to review the literature on tenecteplase in treatment of patients with PE.
Authors:
Sameer Shrivastava; Ankush Sachdeva; Biswajit Paul
Related Documents :
15821824 - Prevalence of thromboembolic disease including superior vena cava and brachiocephalic v...
18314434 - Venous thromboembolism and mortality associated with recombinant erythropoietin and dar...
11197244 - High prevalence of thrombophilic genotypes in patients with acute mesenteric vein throm...
19562294 - Venous thromboembolism prophylaxis in hospitalized patients with pneumonia: a prospecti...
7900274 - Serum sickness secondary to ciprofloxacin use.
15821824 - Prevalence of thromboembolic disease including superior vena cava and brachiocephalic v...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Indian heart journal     Volume:  61     ISSN:  0019-4832     ISO Abbreviation:  Indian Heart J     Publication Date:    2009 Sep-Oct
Date Detail:
Created Date:  2010-07-19     Completed Date:  2010-08-06     Revised Date:  2010-12-23    
Medline Journal Info:
Nlm Unique ID:  0374675     Medline TA:  Indian Heart J     Country:  India    
Other Details:
Languages:  eng     Pagination:  464-6     Citation Subset:  IM    
Affiliation:
Escorts Heart Institute and Research Centre, Okhla, New Delhi, India. sameer_rashmi@hotmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Fibrinolytic Agents / therapeutic use*
Humans
Pulmonary Embolism / drug therapy*,  physiopathology
Randomized Controlled Trials as Topic
Risk Assessment
Thrombolytic Therapy*
Tissue Plasminogen Activator / therapeutic use*
Ventricular Function, Right / drug effects
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 0/tenecteplase; EC 3.4.21.68/Tissue Plasminogen Activator
Comments/Corrections
Comment In:
Indian Heart J. 2010 Jan-Feb;62(1):92

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  "Tenecteplase--the best among the equals.".
Next Document:  Efficacy and safety of tenecteplase in ST elevation myocardial infarction patients from the elaxim I...